文献速递食管与纵隔外科

肿瘤分化程度影响食管腺癌患者新辅助治疗反应及生存

Tumor differentiation impacts response to neoadjuvant therapy and survival in patients with esophageal adenocarcinoma.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-10-01

这项多机构回顾性研究纳入2010年1月至2017年12月接受新辅助放化疗后行食管切除术的550例食管癌患者,比较G1/2与G3肿瘤对新辅助治疗反应及生存的影响,发现两组病理完全缓解率相似,但G3肿瘤食管和淋巴结残留病变更常见,且中位随访63个月时G3患者总生存、绝对生存和无病生存均显著更差,即使达到病理完全缓解也是如此。

要点

  • G3与G1/2肿瘤的病理完全缓解率相似,但G3肿瘤食管和淋巴结残留病变更常见。
  • 中位随访63个月,G3肿瘤患者绝对生存、总生存和无病生存均显著更差。
  • 即使达到病理完全缓解,G3肿瘤患者生存仍显著更差。

核心结论

  • 新辅助治疗反应不受肿瘤分化程度影响,但低分化与更差生存相关,即使达到病理完全缓解也是如此。
  • 作者认为低分化应作为局部晚期食管腺癌临床分期的附加危险因素。

研究设计与样本

  • 多机构回顾性研究,纳入2010年1月至2017年12月接受新辅助放化疗后行食管切除术的食管癌患者。
  • 共550例患者,其中男性485例(88.2%),女性65例;中位年龄61岁。
  • G1/2肿瘤288例(52.4%),G3肿瘤262例;两组新辅助治疗前总体临床分期相似。

主要发现

  • 病理完全缓解(pCR)共87例(15.8%),两组pCR频率相似,但G3肿瘤食管和淋巴结残留病变更常见。
  • 中位随访63个月,G3肿瘤患者绝对生存、总生存和无病生存均显著更差。
  • 即使达到pCR,G3肿瘤患者生存仍显著更差。

临床怎么用

  • 作者认为低分化应作为局部晚期食管腺癌临床分期的附加危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The current staging system for esophageal adenocarcinoma only considers tumor grade in early tumors. The aim of this study was to evaluate the impact of tumor differentiation on response to neoadjuvant chemoradiotherapy and survival in patients with locally advanced esophageal adenocarcinoma. METHODS: This was a multi-institution retrospective review of all patients with esophageal cancer who underwent neoadjuvant chemoradiotherapy followed by esophagectomy from January 2010 to December 2017. Response to neoadjuvant therapy and survival was compared between patients with well- or moderately differentiated (G1/2) tumors versus poorly differentiated (G3) tumors. RESULTS: There were 550 patients, 485 men (88.2%) and 65 women. The median age was 61 years, and the tumor was G1/2 in 288 (52.4%) and G3 in 262 patients. Overall clinical stage before neoadjuvant therapy was similar between groups. Pathologic complete response (pCR) was found in 87 patients (15.8%). The frequency of pCR was similar between groups, but residual disease in the esophagus and lymph nodes was significantly more likely with G3 tumors. Median follow-up was 63 months and absolute survival, overall survival, and disease-free survival were all significantly worse in patients with G3 tumors. Further, even with pCR, patients with G3 tumors had significantly worse survival. CONCLUSIONS: This study showed that response to neoadjuvant therapy was not affected by tumor differentiation. However, poor differentiation was associated with worse survival compared with patients with G1/2 tumors, even among those with pCR. These results suggest that poor differentiation should be considered as an added risk factor for clinical staging in patients with locally advanced esophageal adenocarcinoma.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. McKay SC, Louie BE, Molena D, et al. Tumor differentiation impacts response to neoadjuvant therapy and survival in patients with esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2023. PMID: 37788788. doi:10.1016/j.jtcvs.2023.09.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。